Friday July 14, 2017 0 comments
ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced an exclusive distribution agreement for MiOXSYS® with GryNumber Health, a leading specialty healthcare company serving the fertility market throughout Central and Southeast Europe and Scandinavia.
"We are very pleased to further expand our worldwide distribution network for MiOXSYS,” said Josh Disbrow, Aytu CEO.
“GryNumber Health is an ideal partner for Aytu given their footprint in more than 20 countries in Europe and their specific focus on marketing solutions in the fertility field.
“Our expanding network of distributors for MiOXSYS continues to demonstrate the significant interest and need for an innovative diagnostic platform that has the potential to benefit the millions of men worldwide dealing with infertility."
"GryNumber Health is establishing itself as a leader in the diagnosis and treatment of male and female infertility throughout Europe and we are very enthusiastic about bringing MiOXSYS to our many customers,” said Valdemaras Rodzco, GryNumber Health CEO.
“The MiOXSYS platform is an exciting advancement in male infertility, and we are optimistic about its significant potential in Europe and worldwide. We look forward to a successful partnership with Aytu and helping to further establish MiOXSYS as an important diagnostic that will be beneficial to the millions of European men challenged by infertility."
Aytu said it expects to continue to expand its ex-U.S. distribution channel in line with ramping commercial sales in territories where MiOXSYS is approved while the company pursues regulatory clearance in the U.S. through the FDA's 510(k) pathway.